Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, et al. “Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.” Oncologist 22, no. 2 (February 2017): 189–98. https://doi.org/10.1634/theoncologist.2016-0121.

PMID
28188257
Full Text

Kelley, Michael J., Gautam Jha, Debra Shoemaker, James E. Herndon, Lin Gu, William T. Barry, Jeffrey Crawford, and Neal Ready. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.” Cancer Invest 35, no. 1 (January 2, 2017): 32–35. https://doi.org/10.1080/07357907.2016.1253710.

PMID
27911119
Full Text

Pang, Herbert, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance).” In Journal of Thoracic Oncology, 12:S1367–S1367. ELSEVIER SCIENCE INC, 2017.

Scholars@Duke

Wang, Xiaofei, Xiaowen Cao, Thomas Stinchcombe, Jeffrey Bradley, Alex Adjei, David R. Gandara, Suresh Ramalingam, Herbert Pang, Everett Vokes, and Jeffrey Crawford. “Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials.” In Journal of Thoracic Oncology, 12:S922–23. ELSEVIER SCIENCE INC, 2017.

Scholars@Duke

Crawford, Jeffrey. “Biology and Management of Tumor Cachexia.” In Journal of Thoracic Oncology, 12:S35–36. ELSEVIER SCIENCE INC, 2017.

Scholars@Duke

Poniewierski, Marek S., Eva Culakova, Gary H. Lyman, David C. Dale, and Jeffrey Crawford. “Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review.” In Journal of Thoracic Oncology, 11:S319–S319. ELSEVIER SCIENCE INC, 2016.

Scholars@Duke

Kim, Edward, Michaela Dinan, KM Monirul Islam, Ancilla Fernandes, Lee Schwartzberg, Elisabeth Croft, Julie Brahmer, et al. “Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress.” In Journal of Thoracic Oncology, 11:S308–9. ELSEVIER SCIENCE INC, 2016.

Scholars@Duke

Kim, Edward, Michaela Dinan, Km Monirul Islam, Ancilla Fernandes, Lee Schwartzberg, Elisabeth Croft, Julie Brahmer, et al. “PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress: Topic: Medical Oncology.” J Thorac Oncol 11, no. 11S (November 2016): S308–9. https://doi.org/10.1016/j.jtho.2016.09.096.

PMID
27969528
Full Text

Poniewierski, Marek S., Eva Culakova, Gary H. Lyman, David C. Dale, and Jeffrey Crawford. “PS01.76: Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review: Topic: Medical Oncology.” J Thorac Oncol 11, no. 11S (November 2016): S319. https://doi.org/10.1016/j.jtho.2016.09.111.

PMID
27969543
Full Text

De Ruysscher, D., B. Lueza, C. Le Péchoux, D. H. Johnson, M. O’Brien, N. Murray, S. Spiro, et al. “Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.” Ann Oncol 27, no. 10 (October 2016): 1818–28. https://doi.org/10.1093/annonc/mdw263.

PMID
27436850
Full Text

Pages